What is Arcturus Therapeutics Holdings Current Ratio?
Arcturus Therapeutics HoldingsARCT +4.77%54 Current Ratio is 6.31 as of Mar. 2026, which is 37% above its 10-year median of 4.61. GuruFocus rates ARCT with a GF Score™ of 54/100 and a GF Value™ of $4.41 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,416 Biotechnology companies, Arcturus Therapeutics Holdings ranks better than 65.11% on this metric.
Arcturus Therapeutics Holdings has a current ratio of 6.31. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Arcturus Therapeutics Holdings's Current Ratio or its related term are showing as below:
ARCT'
s Current Ratio Range Over the Past 10 Years
Min: 1.41 Med: 4.61 Max: 25.42
Current: 6.31
During the past 13 years, Arcturus Therapeutics Holdings's highest Current Ratio was 25.42. The lowest was 1.41. And the median was 4.61.
ARCT's Current Ratio is ranked better than 65.11% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs ARCT: 6.31
Arcturus Therapeutics Holdings (NAS:ARCT) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Arcturus Therapeutics Holdings Current Ratio Related Terms
Arcturus Therapeutics Holdings Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcturus Therapeutics Holdings Current Ratio Chart
For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcturus Therapeutics Holdings Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Current Ratio distribution charts can be found below:
* The bar in red indicates where Arcturus Therapeutics Holdings's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcturus Therapeutics Holdings (ARCT) has a Current Ratio of 6.31 as of Mar. 2026. This is 37% above median its historical median of 4.61. Over the past decade, Arcturus Therapeutics Holdings' Current Ratio has ranged from 1.41 to 25.42. According to the industry distribution chart, Arcturus Therapeutics Holdings ranks #494 out of 1416 companies in the Biotechnology industry, placing it in the top 34.9%.
Is Arcturus Therapeutics Holdings' Current Ratio too high?
Arcturus Therapeutics Holdings' current Current Ratio of 6.31 is 37% above median its 10-year median of 4.61. Over the past 10 years, this metric has ranged from a low of 1.41 to a high of 25.42. The Biotechnology industry median Current Ratio is 3.89. Arcturus Therapeutics Holdings' value of 6.31 is 62.4% above this industry median. Based on the distribution chart, Arcturus Therapeutics Holdings ranks #494 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' Current Ratio compare to YDES and RNAC?
According to the Biotechnology industry distribution chart, Arcturus Therapeutics Holdings ranks #494 out of 1416 companies for Current Ratio. This puts Arcturus Therapeutics Holdings in the upper half of its industry. The industry median Current Ratio is 3.89. Arcturus Therapeutics Holdings' value of 6.31 is 62.4% above this benchmark. Historically, Arcturus Therapeutics Holdings' own Current Ratio has ranged from 1.41 to 25.42 over the past decade. While the company's 10-year median is 4.61 vs. the industry median of 3.89, Arcturus Therapeutics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcturus Therapeutics Holdings's current Current Ratio of 6.31 is 62.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcturus Therapeutics Holdings's current Current Ratio is 6.31, which is 37% above median its own 10-year median of 4.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.41, compared to a current price of $7.14 — trading 61.9% above its estimated fair value. The current Current Ratio is 6.31, which is 37% above median its 10-year median of 4.61 and 62.4% above the Biotechnology industry median of 3.89. Arcturus Therapeutics Holdings' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current Current Ratio is 6.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued.
The current stock price of $7.14 is trading 61.9% above its estimated GF Value™ of $4.41.
GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.
Key valuation signals for ARCT:
Current Ratio: 6.31 (37% above median its 10-year median of 4.61)
GF Value™: $4.41 vs. price of $7.14 (61.9% above fair value)
Industry Position: 62.4% above the Biotechnology median (#494 of 1416)
No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcturus Therapeutics Holdings Business Description
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
54GF Score
Get the complete analysis for ARCT
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARCT has been successfully added to your 
